Deoxyribozyme

DGAP-News: sterna biologicals announces dosing of first patient in phase IIa proof-of-concept study with SB010 in moderate to severe asthma

Retrieved on: 
月曜日, 12月 20, 2021
Nitric acid, Hope, Global Initiative, Company, IIA, Hospital, Epigenetics of diabetes Type 2, LABA, The New England Journal of Medicine, Sterna, POC, Today, Pulmonology, Pharmacokinetics, Clinic, ICS, Inhalation, Safety, Inflammation, Patient, Global Initiative for Asthma, Ulcerative colitis, Hannover Medical School, Factor X, GINA, COPD, Bronchospasm, Atopic dermatitis, Immunomodulation, Chronic obstructive pulmonary disease, In Practice Systems Limited, Asthma, Deoxyribozyme, Gesellschaft mit beschränkter Haftung, Aquaculture, Pharmaceutical industry

"We are pleased that the first patient has been treated in our GIANT-1 trial with inhaled SB010 in patients with uncontrolled moderate to severe asthma," said Dr. Marion Wencker, Chief Medical Officer of sterna biologicals.

Key Points: 
  • "We are pleased that the first patient has been treated in our GIANT-1 trial with inhaled SB010 in patients with uncontrolled moderate to severe asthma," said Dr. Marion Wencker, Chief Medical Officer of sterna biologicals.
  • "I am excited about the potential SB010 holds in treating patients with moderate to severe uncontrolled asthma.
  • In this study, sterna will for the first time, combine pharmacological and digital therapy by integrating VisionHealth's Kata(R) Clinical into the trial.
  • Consequently, the Company's therapeutic candidates containing hgd40, SB010 and SB012, address several inflammatory processes simultaneously and rebalance an overall dysregulated immune response.

DGAP-News: VisionHealth's Kata(R) Clinical app to support sterna biologicals' clinical Phase IIa asthma trial

Retrieved on: 
火曜日, 11月 23, 2021
Patient, Gesellschaft mit beschränkter Haftung, COPD, Trial of the century, Chronic obstructive pulmonary disease, Automation, Safety, CEO, Clinical trial, Technology, Industry, Data management, Data collection, Asthma, Company, POC, Single-frequency network, Deoxyribozyme, Contract research organization, Inhalation, Factor X, Form 1099, Physician, App, Atopic dermatitis, CRO, Ulcerative colitis, Artificial intelligence, Collection, Certification, Knowledge, Sterna, Chronic lung disease, Degenerative disease, Disease, Intelligence, In Practice Systems Limited, Pharmaceutical industry, Medical device, VisionHealth, Kata(R), sterna biologicals, VISIONHEALTH, KATA(R), STERNA BIOLOGICALS

Kottmann GmbH & Co. KG, a Clinical Research Organization (CRO) that will apply Kata(R) Clinical also beyond this trial.

Key Points: 
  • Kottmann GmbH & Co. KG, a Clinical Research Organization (CRO) that will apply Kata(R) Clinical also beyond this trial.
  • Kata(R) Clinical is a modified Kata(R) app for Clinical Trials from VisionHealth's artificial intelligence proprietary platform for inhalation therapy support.
  • The App is offered to pharma, biotech and CRO partners to support clinical trials in the respiratory field.
  • For sterna's asthma trial, VisionHealth adapted Kata(R) Clinical to specifically support the run-in period for patient preparation and therapy adherence, ensuring the correctly performed inhalation with SB010.

DGAP-News: sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS RECEIVES APPROVAL FOR INNOVATIVE PHASE II A STUDY DESIGN IN ASTHMA COMBINING A NOVEL ANTISENSE-BASED TREATMENT WITH A DIGITAL THERAPY

Retrieved on: 
火曜日, 11月 23, 2021
Patient, Gesellschaft mit beschränkter Haftung, COPD, Safety, Inflammation, Company, Asthma, POC, IIA, Deoxyribozyme, Inhalation, Factor X, The New England Journal of Medicine, Atopic dermatitis, Chronic obstructive pulmonary disease, DIGITAL, Ulcerative colitis, Artificial intelligence, Medical device, ICS, Sterna, Chronic lung disease, LABA, CTA, Degenerative disease, Immunomodulation, Mark (given name), In Practice Systems Limited, Aquaculture, Pharmaceutical industry

DGAP-News: sterna biologicals GmbH & Co. KG

Key Points: 
  • DGAP-News: sterna biologicals GmbH & Co. KG
    sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS RECEIVES APPROVAL FOR INNOVATIVE PHASE II A STUDY DESIGN IN ASTHMA COMBINING A NOVEL ANTISENSE-BASED TREATMENT WITH A DIGITAL THERAPY
    The issuer is solely responsible for the content of this announcement.
  • -Phase IIa proof-of-concept (POC) study with novel catalytic antisense oligonucleotide SB010 in patients with moderate to severe asthma initiated.
  • The combination of these functions specifically tailored to the study design will ensure optimal data reliability and meaningfulness.
  • The company develops innovative and unique digital health solutions enabling sustainable improvements in existing standard therapy for patients with chronic lung diseases like asthma and COPD.